Evaluation of drug resistance of patients with tuberculosis over a period of thirty years Source: Eur Respir J 2002; 20: Suppl. 38, 549s Year: 2002
The profile of patients with pulmonary tuberculosis younger then 40 years Source: Eur Respir J 2002; 20: Suppl. 38, 363s Year: 2002
3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review Source: Eur Respir J, 52 (1) 1800395; 10.1183/13993003.00395-2018 Year: 2018
Treatment outcomes of tuberculosis patients under directly observed therapy (DOT) for three years Source: Eur Respir J 2004; 24: Suppl. 48, 653s Year: 2004
Higher adverse drug reactions but better completion rate of twelve-dose weekly rifapentine plus isoniazid comparing with nine-month daily isoniazid for latent tuberculosis infection among patients under maintenance dialysis Source: Virtual Congress 2020 – Tuberculosis: part 1 Year: 2020
Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population Source: Eur Respir J 2005; 26: Suppl. 49, 624s Year: 2005
Neonatal antibiotic treatment increases the risk of asthma at age 12 years Source: International Congress 2017 – Insight into childhood asthma and paediatric pulmonology Year: 2017
The experience of directly observed therapy in Esrefpasa tuberculosis dispensary for two years Source: Eur Respir J 2005; 26: Suppl. 49, 645s Year: 2005
The characteristics of previous tuberculosis treatment programmes in patients with tuberculosis relapses Source: Eur Respir J 2001; 18: Suppl. 33, 473s Year: 2001
The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007
Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience Source: Eur Respir J 2011; 38: 888-894 Year: 2011
Reduced moxifloxacin exposure in patients with tuberculosis and diabetes Source: Eur Respir J, 54 (3) 1900373; 10.1183/13993003.00373-2019 Year: 2019
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
The effect of hospitalization and disease itself on smoking sessation of patients with tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 155s Year: 2004
One year follow-up of T-SPOT. TB results in treated patients with active tuberculosis Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007
TB at patients older than 80 years Source: Eur Respir J 2005; 26: Suppl. 49, 420s Year: 2005
Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study Source: Eur Respir J, 52 (6) 1801470; 10.1183/13993003.01470-2018 Year: 2018
Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy Source: Eur Respir J 2001; 18: Suppl. 33, 314s Year: 2001
The causes of ineffectiveness of treatment of tuberculosis in children Source: Eur Respir J 2005; 26: Suppl. 49, 649s Year: 2005